Scribe Therapeutics Inc. SCTX
12.11 USD -1.11 (-8.39%)
As ofNov 20, 2026, 1:47 PM EST
12.05 Day range 13.40
12.05 52-week range 39.60
- YTD
- -36.16%
- 1 year
- -36.16%
No chart data for this range yet.
- Market cap
- 229.35M
- EPS (ttm)
- -6.35
- YTD return
- -36.16%
- 1-year return
- -36.16%
- Volume
- 167.29K
- Avg volume
- 401.37K
- Open
- 12.87
- Previous close
- 13.22
- Day's range
- 12.05 – 13.40
- 52-week range
- 12.05 – 39.60
Fundamental scorecard
3 of 25 checks passed on SCTX’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth No data
- Profitability No data
- Financial health 3 of 5
- Dividend No data
Statements to Sep 30, 2026.
Financials — quick view
SCTX Revenue — quarterly 1.64M
SCTX Net income — quarterly -9.86M
SCTX EPS — quarterly -0.68
News
HC Wainwright & Co. Reiterates Buy on Scribe Therapeutics, Maintains $60 Price Target
Scribe Therapeutics Reports Updated Preclinical Data From STX-1150 And STX-1200 Programs At AHA Scientific Sessions 2026
Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026 Scribe Therapeutics Q3 EPS $(0.68) Beats $(2.06) Estimate, Sales $1.600M Miss $3.113M Estimate
Scribe Therapeutics To Present Data In American Heart Association’s Scientific Sessions On Its Three Clinical Programs
Your note
Sign in to keep a note on SCTX — it syncs with the Stock Master app.
